- Conditions
- Advanced Solid Tumors
- Interventions
- OKI-179
- Drug
- Lead sponsor
- OnKure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fatty Acid Oxidation Disorders
- Interventions
- Low Dose REN001, High Dose REN001
- Drug
- Lead sponsor
- Reneo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
- Interventions
- OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib
- Drug
- Lead sponsor
- OnKure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- RAS Mutation, NRAS Gene Mutation, Melanoma
- Interventions
- OKI-179 + binimetinib
- Drug
- Lead sponsor
- OnKure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 9 more
- Conditions
- Primary Mitochondrial Myopathy
- Interventions
- Mavodelpar, Placebo
- Drug
- Lead sponsor
- Reneo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- La Jolla, California • Gainesville, Florida • Boston, Massachusetts + 6 more
- Conditions
- Fatty Acid Oxidation Disorder
- Interventions
- Not listed
- Lead sponsor
- Reneo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Pittsburgh, Pennsylvania • Nashville, Tennessee